Navigation Links
New Arthritis Drug Linked to Increased Risk of Heart Attacks

The new arthritis drug Prexige is said to be linked to an increased risk of heart attacks and strokes and arthritis sufferers have been warned to exercise caution in its use.//

The federal government's Pharmaceutical Benefits Scheme (PBS) will make the drug Prexige (generic name, lumiracoxib) available from Tuesday. The drug is the first COX-2 inhibitor to be marketed in Australia since it was found in 2004 that these group of drugs increased risk of heart attacks and strokes.

Popular arthritis drug Vioxx was taken off shelves while the drug Celebrex was forced to carry warnings about heart disease ever since this revelation was made public in 2004. The National Prescribing Service has released an independent review warning that the evidence of long-term cardiovascular safety of the new drug is limited.

Dr Peter Roush from the National Prescribing Service says that the safer option for patients should be to first try to manage their condition with over-the-counter painkillers.

He said, "People with osteoarthritis should first consider an effective dose of paracetamol and speak with their doctor if they need a medicine to manage the pain. For some people, lumiracoxib may be an appropriate alternative to other medicines in the same class. This medicine has benefits for people at risk of a stomach ulcer, but we don't know everything about its risk to the heart and brain."

COX-2 inhibitors have been non-steroidal anti-inflammatory drugs (NSAIDs) which were developed as an alternative to older NSAIDs like ibuprofen, Voltaren, or naproxen. And studies showed that lumiracoxib caused fewer serious ulcer complications such as bleeding, than ibuprofen or naproxen. He said, "But people who are likely to have stomach trouble should use lumiracoxib with caution, as it does not eliminate the risk of getting an ulcer. There's limited evidence available about the long-term risk to your heart when using this medicine, but we do kn ow you should not use it if you have, or are likely to have, cardiovascular disease."

The medicine is recommended for use for the shortest possible time, ideally when symptoms flare up or before painful activities.


'"/>




Related medicine news :

1. Another ray of hope for Arthritis Sufferers
2. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
3. B Vitamin protects and lowers toxicity of Arthritis Drug
4. FDA Approves New Arthritis Drug, Bextra
5. Risk Of Developing Arthritis
6. Arthritis Drug May Cause Liver Damage
7. Arthritis drug can prolong life
8. New treatment for Rheumatoid Arthritis
9. Important cause of Arthritis
10. Personality Impacts Arthritis
11. New Rheumatoid Arthritis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... ... April 25, 2017 , ... ... products, is introducing Flexadin UCII, part of the EQUISTRO line, at this week’s ... health in horses at the immunologic level. , The scientifically-developed Flexadin UCII supports ...
(Date:4/24/2017)... ... ... Michael Vick announced his retirement earlier this year from the NFL after ... pick in the 2001 NFL Draft, to the Atlanta Falcons, made four Pro Bowl ... rushing yards by a quarterback (6,109) and the most rushing yards by a quarterback ...
(Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director ... Communication of Education Research Award. The award honors scholars exemplary in their capacity ... a scholar who has demonstrated the capacity to deepen the public’s understanding and ...
(Date:4/24/2017)... ... 24, 2017 , ... Sean Fay is the undisputed king of the infomercial. ... and the George Foreman Grill (which sold more than 100 million units worldwide), he ... years. , Now, due to changes in the broadcast media landscape, the once ever-present ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... that they are seeking public support to bring their novel lifesaving device for ... wearable device packed with medical-grade sensors, specially designed to read a child’s vital ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
(Date:4/18/2017)... 2017 Viverae ® , a leader in ... of IBM ® Watson Campaign Automation, implementing behavioral ... for a personalized experience. Through digital engagement, the platform ... in real time. The enhanced experience drives engagement by ... wherever they are in their journey to health. ...
(Date:4/18/2017)... April 18, 2017  Astute Medical, Inc., developer of ... to be presented at the 2017 National Kidney Foundation ... and continues through April 22. Physicians will present data ... to assess risk for acute kidney injury (AKI) during ... (ADHF). Elevated levels of TIMP-2 and ...
Breaking Medicine Technology: